iPSC Spheroids with Microglia Model Human Myelin Injury and Repair in Multiple Sclerosis

The model required six years of iterative engineering at The Florey Institute and Monash University. Researchers differentiated induced pluripotent stem cells into neurons, oligodendrocytes, astrocytes and microglia, then assembled them into 3D spheroids that spontaneously formed extensive myelinated axon networks. Introduction of activated microglia triggered focal myelin loss that could be quantified by electron microscopy and myelin basic protein staining, creating a human-cell platform for testing repair kinetics.

Rodent models have historically identified compounds that fail in patients because rodent oligodendrocyte precursors and immune responses differ substantially from human cells. This spheroid system permits direct observation of endogenous human remyelination rates after controlled injury, addressing the translational gap. It also allows simultaneous screening of candidate molecules for both protective and regenerative effects on the same donor-derived tissue.

No absolute or relative clinical outcome data yet exist; the study reports only cellular morphology and marker expression changes. As an in-vitro system it cannot capture blood-brain-barrier trafficking, systemic immune priming or long-term circuit-level consequences. Next required steps are independent replication across multiple iPSC lines, correlation with existing rodent remyelination assays, and blinded testing of known and novel compounds to establish predictive validity before any clinical translation.

Evidence quality is moderate: the design is an interventional cell-culture study with internal controls, but lacks the complexity of an intact nervous system and has not been externally validated. Larger multi-lab studies with standardized injury and repair endpoints are needed before the platform can reliably guide drug development pipelines.